[Double blockade of the renin-angiotensin system (RAS): what has the ONTARGET study taught us?].
Del Vecchio
Lucia
L
Divisione di Nefrologia e Dialisi, Ospedale A. Manzoni, Lecco, Italy. luciadelvecchio@yahoo.com
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D001565:Benzoates / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D017257:Ramipril / Q000009:adverse effects* / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000187:drug effects*; D000077333:Telmisartan
D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D017257:Ramipril; D000077333:Telmisartan